Objective: To evaluate the clinical characteristics and survival outcomes of patients with de novo grade 3 or transformed follicular lymphoma (FL). Methods: Fifty-two patients treated at Peking University Cancer Hospital between January 2009 and September 2017 were assessed, including 28 patients with FL 3A grade, 13 patients with FL 3B grade, 11 patients with transformed FL. Baseline characteristics, survival and prognostic factors were analyzed. Results: ① Twenty-six male and 26 female patients were enrolled, including 28 patients with FL 3A grade, 13 patients with FL 3B grade, 11 patients with transformed FL. ②The 3-year progression-free survival (PFS) and overall survival (OS) for the entire cohort were 56.0% and 80.6%, respectively. Patients with international prognostic index (IPI) score 0-1 demonstrated significantly better 3-year PFS (80.3% vs 20.1%; t=18.902, P<0.001) and OS (95.7% vs 57.0%; t=10.406, P<0.001) than patients with IPI score 2-3. Three-year PFS (94.1% vs 37.2% vs 25.2%; P=0.002) and OS (100.0% vs 76.0% vs 59.8%; P=0.020) were also significantly different among patients with FLIPI 1 score 0-1, 2, ≥3. FLIPI 2 score was also identified as a prognostic factor for 3-year PFS (68.4%, 0, 0; P=0.001) and OS(87.5%, 76.2%, 0; P=0.003). ③Multivariate analysis indicated a significant association of PFS (HR=3.536, P=0.015) and OS (HR=15.713, P=0.015) with IPI. FLIPI 2 was associated with OS (score 0-1, HR=0.078, P=0.007; score 2, HR=0.080, P=0.022). Conclusion: De novo grade 3 or transformed FL might be a group of curable disease with current treatment strategies. IPI is still a prognostic tool in this scenario.
目的： 探讨初治3级或伴有大B细胞转化滤泡淋巴瘤（FL）患者的临床特征及预后。 方法： 收集2009年1月至2017年9月在北京大学肿瘤医院诊断治疗的52例FL患者资料，对患者的基本临床特征、生存及预后因素进行统计学分析。 结果： ①52例患者中，男女各26例，其中3A级28例，3B级13例，伴大B细胞转化11例。②整组患者的3年无进展生存（PFS）率为56.0%，3年总生存（OS）率为80.6%。IPI评分0~1分者较2~3分者的3年PFS率（80.3%对20.1%，t=18.902，P<0.001）和OS率（95.7%对57.0%，t=10.406，P<0.001）高；FLIPI 1评分低、中、高危组患者的3年PFS率分别为94.1%、37.2%、25.2%（P=0.002），3年OS率分别为100%、76.0%、59.8%（P=0.020），FLIPI 2评分低、中、高危组患者的3年PFS率分别为68.4%、0、0（P=0.001），3年OS率分别为87.5%、76.2%、0（P=0.003），差异均有统计学意义。③多因素分析显示，IPI评分≥2分是影响患者PFS（HR=3.536，P=0.015）和OS（HR=15.713，P=0.015）的不良预后因素；FLIPI 2评分与患者OS（以≥3分为参照，0~1分：HR=0.078，P=0.007；2分：HR=0.080，P=0.022）显著相关。 结论： 以现有治疗手段，初治高级别FL和伴大B细胞转化FL有可能治愈，IPI评分仍可以预测该组患者预后。.
Keywords: Cell transformation, neoplastic; High grade; Lymphoma, follicular; Prognosis.